Warfarin induces cardiovascular damage in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 11, 2013, Pages 2618-2624

  Krüger, Thilo ^a   Oelenberg, Stephan ^a   Kaesler, Nadine ^a   Schurgers, Leon J ^b   Van De Sandt, Annette M ^c   Boor, Peter ^a,d,e   Schlieper, Georg ^a   Brandenburg, Vincent M ^a   Fekete, Bertalan C ^f   Veulemans, Verena ^c   Ketteler, Markus ^g   Vermeer, Cees ^h   Jahnen Dechent, Willi ^a   Floege, Jürgen ^a   Westenfeld, Ralf ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Physics and Informatics   (Slovakia)

^f Military Hospital Budapest   (Hungary)

^g KLINIKUM COBURG   (Germany)

^h VitaK Inc   (Netherlands)

Author keywords

aortic valve stenosis; matrix Gla protein; pulse wave velocity; vascular calcification; vitamin K; warfarin

Indexed keywords

CALCIUM; FARNOQUINONE; OSTEOCALCIN; PHYTOMENADIONE; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; ECHOCARDIOGRAPHY; HEART; HEART MUSCLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

AORTIC VALVE STENOSIS; MATRIX GLA PROTEIN; PULSE-WAVE VELOCITY; VASCULAR CALCIFICATION; VITAMIN K; WARFARIN;

ANIMALS; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; AORTA; APOPTOSIS; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MUSCLE, SMOOTH, VASCULAR; PULSATILE FLOW; RISK FACTORS; VASCULAR CALCIFICATION; VITAMIN K 1; VITAMIN K 2; WARFARIN;

EID: 84887045526     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302244     Document Type: Article

References (41)

1. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. Calcifcation in atherosclerosis: bone biology and chronic infammation at the arterial crossroads. Proc Natl Acad Sci USA. 2003;100:11201-11206.
2. Abedin M, Tintut Y, Demer LL. Vascular calcifcation: mechanisms and clinical ramifcations. Arterioscler Thromb Vasc Biol. 2004;24:1161-1170.
3. Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcifcation of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA. 2000;283:2810-2815.
4. Greenland P, Lloyd-Jones D. Time to end the mixed-and often incorrect-messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2007;50:2133-2135.
5. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG. Infuence of lipid-lowering therapy on the progression of coronary artery calcifcation: a prospective evaluation. Circulation. 2002;106:1077-1082.
6. Schinke T, McKee MD, Karsenty G. Extracellular matrix calcifcation: where is the action? Nat Genet. 1999;21:150-151.
7. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcifcation of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
8. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD. Cartilage formation and calcifcation in arteries of mice lacking matrix Gla protein. Connect Tissue Res. 2003;44(suppl 1):272-278.
9. Shanahan CM. Infammation ushers in calcifcation: a cycle of damage and protection? Circulation. 2007;116:2782-2785.
10. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcif-cation inhibitor in need of vitamin K. Thromb Haemost. 2008;100:593-603.
11. Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ. Vascular calcifcation: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012;26:155-166.
12. Schurgers LJ, Shearer MJ, Hamulyák K, Stöcklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood. 2004;104:2682-2689.
13. Koos R, Krueger T, Westenfeld R, Kühl HP, Brandenburg V, Mahnken AH, Stanzel S, Vermeer C, Cranenburg EC, Floege J, Kelm M, Schurgers LJ. Relation of circulating Matrix Gla-Protein and anticoagu-lation status in patients with aortic valve calcifcation. Thromb Haemost. 2009;101:706-713.
14. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D. Post-translational modifcations regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcifcation. J Thromb Haemost. 2007;5:2503-2511.
15. Khavandgar Z, Roman H, Li J, Lee S, Vali H, Brinckmann J, Davis EC, Murshed M. Elastin haploinsuffciency impedes the progression of arterial calcifcation in MGP-defcient mice. J Bone Miner Res. July 15, 2013. doi: 10.1002/jbmr.2039. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2039/ abstract;jsessionid=717E16A93C0BD8956AC6C3EB2312563D.d03t04. Accessed September 5, 2013.
16. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277:4388-4394.
17. Yao Y, Zebboudj AF, Shao E, Perez M, Boström K. Regulation of bone mor-phogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem. 2006;281:33921-33930.
18. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733-741.
19. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcifcation of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400-1407.
20. Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, Reutelingsperger CP, Cleutjens JP, Vermeer C. Novel confor-mation-specifc antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcifcation. Arterioscler Thromb Vasc Biol. 2005;25:1629-1633.
21. Moncada RM, Venta LA, Venta ER, Fareed J, Walenga JM, Messmore HL. Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcifcation. Radiology. 1992;184:437-439.
22. Yagami K, Suh JY, Enomoto-Iwamoto M, Koyama E, Abrams WR, Shapiro IM, Pacifci M, Iwamoto M. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossifcation in the limb. J Cell Biol. 1999;147:1097-1108.
23. Keutel J, Jörgensen G, Gabriel P. [A new autosomal-recessive hereditary syndrome. Multiple peripheral pulmonary stenosis, brachytelephalangia, inner-ear deafness, ossifcation or calcifcation of cartilages]. Dtsch Med Wochenschr. 1971;96:1676-81 passim.
24. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carbox-ylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013;19:217-226.
25. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007;109:2823-2831.
26. Koos R, Mahnken AH, Mühlenbruch G, Brandenburg V, Pfueger B, Wildberger JE, Kühl H P. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96:747-749.
27. Schurgers LJ, Aebert H, Vermeer C, Bültmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood. 2004;104:3231-3232.
28. Rennenberg RJ, de Leeuw PW, Kessels AG, Schurgers LJ, Vermeer C, van Engelshoven JM, Kemerink GJ, Kroon AA. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest. 2010;40:344-349.
29. Weijs B, Blaauw Y, Rennenberg RJ, Schurgers LJ, Timmermans CC, Pison L, Nieuwlaat R, Hofstra L, Kroon AA, Wildberger J, Crijns HJ. Patients using vitamin K antagonists show increased levels of coronary calcifca-tion: an observational study in low-risk atrial fbrillation patients. Eur Heart J. 2011;32:2555-2562.
30. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ. Effect of vitamin K2 supplementation on functional vitamin K defciency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59:186-195.
31. Schlieper G, Westenfeld R, Brandenburg V, Ketteler M. Inhibitors of cal-cifcation in blood and urine. Semin Dial. 2007;20:113-121.
32. Chen NX, Moe SM. Uremic vascular calcifcation. J Investig Med. 2006;54:380-384.
33. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcifcation: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147-1154.
34. Naik V, Leaf EM, Hu JH, Yang HY, Nguyen NB, Giachelli CM, Speer MY. Sources of cells that contribute to atherosclerotic intimal calcifcation: an in vivo genetic fate mapping study. Cardiovasc Res. 2012;94:545-554.
35. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcifcation and medial degeneration. Circ Res. 2008;102:1529-1538.
36. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcifcation in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcifcation in ESRD. J Am Soc Nephrol. 2004;15:2857-2867.
37. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, Haendeler J, Berk BC. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol. 2004;37:881-887.
38. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
39. van den Broek FA, Beynen AC. The infuence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. Lab Anim. 1998;32:483-491.
40. van den Broek FA, Beems RB, van Tintelen G, Lemmens AG, Fielmich-Bouwman AX, Beynen AC. Co-variance of chemically and histologically analysed severity of dystrophic cardiac calcifcation in mice. Lab Anim. 1997;31:74-80.
41. Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin K-antagonists accelerate atherosclerotic calcifcation and induce a vulnerable plaque phenotype. PLoS ONE. 2012;7:e43229.